Press Release

20 April 2011

LIDCO GROUP PLC

("LiDCO" or the "Company")

Director's Share Dealings

LiDCO Group Plc (AIM:LID), the UK-based hemodynamic monitoring company, today announces the purchase by Paul Clifford, Finance Director, of Ordinary Shares of 5 pence each in the Company on 19 April 2011 at 14.625 pence each. Subsequent to these share purchases, Mr Clifford's interest in the Company is shown below:

Director

Number of

shares purchased

Total number of shares now held

Total number

of  share options held

Percentage of existing share capital

Paul Clifford

25,000

600,000

719,650

0.34

- Ends -

For further information, please contact:

LiDCO Group Plc

Terry O'Brien (CEO)

Tel: +44 (0)20 7749 1500

Paul Clifford (Finance Director)

Theresa Wallis (Chairman)

www.lidco.com

FinnCap

Geoff Nash / Henrik Persson  

Stephen Norcross (broking)

Tel: +44 (0)20 7600 1658

www.finncap.com

Media enquiries:

Abchurch

Adam Michael / Joanne Shears /

Simone Elviss / Claire Dickinson

Tel: +44 (0) 20 7398 7728

simone.elviss@abchurch-group.com

www.abchurch-group.com

About LiDCO Group Plc

LiDCO is a supplier of minimally invasive hemodynamic equipment to hospitals, to monitor the amount of blood flowing around the body and ensure that vital organs are adequately oxygenated. LiDCO's products facilitate the measurement, analysis, audit, training and sharing of real-time and historic hemodynamic data, in both critical care units and the operating theatre.

Scientific evidence is increasingly linking the optimisation of patients' hemodynamic status with better outcomes and reduced hospital stays and LiDCO's computer-based technology, developed at St Thomas' Hospital in London, has been shown to significantly reduce morbidity and complications, length of stay and overall costs associated with major surgery.

Key Products:

LiDCOplus: a computer-based platform monitor used in the Intensive Care Unit for real-time continuous display of hemodynamic parameters including cardiac output, oxygen delivery and fluid-volume responsiveness (PPV% and SVV%)

LiDCOrapid: a cardiac output monitor designed specifically for use in the operating theatre for fluid and drug management. The monitor enables anesthetists to get accurate and immediate feedback on the patient's fluid and hemodynamic status - a key measure of overall well-being before, during and after surgery.  The LiDCOrapid provides:

· 

early and rapid warning of hemodynamic change to aid choice of therapeutic route: fluid or drug

· 

quantification of hemodynamic response,

· 

guidance on effective delivery of fluids to ensure the right amount at the right time

LiDCOview: an easy-to-use graphical display of historical LiDCOplus and LiDCOrapid hemodynamic data.

All LiDCO monitors use single-patient disposables (sensors or smartcards) which provide an ongoing revenue stream. 

Clinical Validation & Education

LiDCO has been selected as the sole technology for two ongoing multi-centre government-funded studies in the UK and US. OPTIMISE is sponsored by the UK Government for optimising cardiovascular management in high-risk abdominal surgery patients and in the US, MOnIToR is a US Government sponsored transplantation donor organ optimisation study. The Company has also developed a hemodynamic workshop at St George's Hospital, London.

LiDCO Distribution Network:

LiDCO products are sold through Covidien's sales force in the US. LiDCO's strategy is to sell directly to hospitals in the UK, and through a network of specialty critical care and anesthesia distributors in the rest of the world.

LiDCO's sales office is in Cambridge, its manufacturing facility and headquarters are in London and its shares are traded on AIM. For more information please see www.lidco.com.

LiDCO Ltd Sales and Marketing, Unit M South Cambridge Business Park, Babraham Road, Sawston, Cambridge CB22 3JH, UK   

Telephone: +44 (0) 1223 830666  Fax: +44 (0) 1223 837241  VAT number 672 4757 08